Affirmed Therapeutics BV (AFMD) Downgraded to Sell at Zacks Investment Research
According to Zacks, “Affimed Therapeutics B.V. is a clinical-stage biopharmaceutical company. It is focused on discovering and developing cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology. The Company’s TandAbs has the ability to bring NK-cells or T-cells into proximity and trigger a signal cascade that leads to the destruction of cancer cells. Its product pipeline includes AFM13, AFM11 and AFM21. Affimed Therapeutics B.V. is headquartered in Heidelberg, Germany. “
Other research analysts also recently issued reports about the stock. Leerink Swann downgraded shares of Affirmed Therapeutics BV from an outperform rating to a market perform rating and decreased their target price for the stock from $8.00 to $3.00 in a research note on Friday, August 12th. Jefferies Group reaffirmed a hold rating on shares of Affirmed Therapeutics BV in a research note on Tuesday, August 9th. One analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the company’s stock. Affirmed Therapeutics BV has an average rating of Hold and a consensus target price of $8.63.
Shares of Affirmed Therapeutics BV (NASDAQ:AFMD) opened at 2.40 on Wednesday. The firm’s market capitalization is $80.37 million. The company’s 50 day moving average is $2.71 and its 200-day moving average is $3.20. Affirmed Therapeutics BV has a one year low of $2.25 and a one year high of $8.42.
Affirmed Therapeutics BV (NASDAQ:AFMD) last announced its earnings results on Wednesday, August 10th. The biopharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by $0.05. Affirmed Therapeutics BV had a negative net margin of 440.97% and a negative return on equity of 49.84%. The company had revenue of $2.07 million for the quarter, compared to the consensus estimate of $2.10 million. During the same quarter in the previous year, the firm earned ($0.19) earnings per share. The company’s revenue for the quarter was down 6.4% compared to the same quarter last year. Equities analysts expect that Affirmed Therapeutics BV will post ($1.12) EPS for the current year.
Hedge funds have recently added to or reduced their stakes in the company. Geode Capital Management LLC raised its stake in Affirmed Therapeutics BV by 6.8% in the first quarter. Geode Capital Management LLC now owns 29,204 shares of the biopharmaceutical company’s stock worth $109,000 after buying an additional 1,856 shares during the last quarter. Paloma Partners Management Co purchased a new position in shares of Affirmed Therapeutics BV during the second quarter valued at approximately $142,000. Moore Capital Management LP purchased a new position in shares of Affirmed Therapeutics BV during the first quarter valued at approximately $281,000. BlackRock Institutional Trust Company N.A. raised its position in shares of Affirmed Therapeutics BV by 1.6% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 108,911 shares of the biopharmaceutical company’s stock valued at $407,000 after buying an additional 1,713 shares in the last quarter. Finally, State Street Corp raised its position in shares of Affirmed Therapeutics BV by 7.7% in the first quarter. State Street Corp now owns 220,885 shares of the biopharmaceutical company’s stock valued at $823,000 after buying an additional 15,714 shares in the last quarter. Institutional investors and hedge funds own 42.86% of the company’s stock.
Affirmed Therapeutics BV Company Profile
Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company’s product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body’s own immune system to fight tumor cells.
Receive News & Stock Ratings for Affirmed Therapeutics BV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affirmed Therapeutics BV and related stocks with our FREE daily email newsletter.